Raymond James Financial Inc. Acquires Shares of 374,641 Hologic, Inc. (NASDAQ:HOLX)

Raymond James Financial Inc. acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 374,641 shares of the medical equipment provider's stock, valued at approximately $27,007,000. Raymond James Financial Inc. owned about 0.17% of Hologic at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of HOLX. General Partner Inc. acquired a new position in shares of Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment raised its position in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. raised its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Stock Up 0.3 %

Shares of HOLX stock traded up $0.16 on Tuesday, hitting $61.98. The stock had a trading volume of 3,766,525 shares, compared to its average volume of 2,401,801. The firm has a market capitalization of $13.91 billion, a price-to-earnings ratio of 19.55, a P/E/G ratio of 2.14 and a beta of 0.97. The stock's 50 day moving average is $66.94 and its 200-day moving average is $74.51. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $60.33 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research analyst reports. Raymond James reaffirmed an "outperform" rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Royal Bank of Canada dropped their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Finally, Stephens reaffirmed an "overweight" rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.